Skip to main content
. Author manuscript; available in PMC: 2015 Dec 22.
Published in final edited form as: Free Radic Res. 2009 Jul 1;43(9):783–795. doi: 10.1080/10715760903062887

Figure 5. A, TM cells obtained from nonglaucomatous subjects treated with TGFβ1 or 2 showed reduced expression of PRDX6.

Figure 5

Cells (P3) were treated with TGFβs (1 or 2ng/ml) for 72h. Cell extract was prepared and Western blot was conducted using PRDX6 specific antibody. Results disclosed that TGFβ1/2 treatment of TM cells resulted in suppression of the PRDX6 expression, and the effect of TGFβ2 was more prominent than TGFβ1. B, Western blot showing that TGFβ-induced abnormal expression of ECM proteins in TM cells was reversed by PRDX6 delivery. Cells were treated with TGF-β1 at 1 ng/ml for 3 days. In parallel experiments, cells were supplied with TAT-HA-PRDX6 (4 µg/ml) 3 h prior to TGFβ treatment to evaluate its ability to prevent TGFβ-induced overexpression of ECM proteins. Cells supplied with PRDX6 showed reversal of the TGFβ-induced overmodulation of proteins (lane 3, panels; a-e).